AUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will host a key opinion leader (KOL) webinar to discuss topline results from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials in greater detail. Management will be joined by three esteemed thought leaders in the field of endocrinology:
Virtual KOL Event: Review of Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency Wednesday, December 6, 2023 | 1:30 PM EST
To register for the virtual KOL Event, please click through the link here.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$3.4B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.02 |
Daily Change: | 0.02 0.67 |
Daily Volume: | 26,359 |
Market Cap: | US$24.520M |
April 18, 2024 March 20, 2024 March 07, 2024 November 07, 2023 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB